Table of Contents Author Guidelines Submit a Manuscript
Computational and Mathematical Methods in Medicine
Volume 2013 (2013), Article ID 282398, 4 pages
http://dx.doi.org/10.1155/2013/282398
Review Article

Antibody Drug Conjugate Bioinformatics: Drug Delivery through the Letterbox

Bioinformatics & Medical Informatics Team, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece

Received 29 May 2013; Accepted 11 June 2013

Academic Editor: Carla Sofia Carvalho

Copyright © 2013 Dimitrios Vlachakis and Sophia Kossida. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M.-P. Lefranc and G. Lefranc, The Immunoglobulin FactsBook, Academic Press, London, UK, 2001.
  2. Y. V. Kovtun and V. S. Goldmacher, “Cell killing by antibody-drug conjugates,” Cancer Letters, vol. 255, no. 2, pp. 232–240, 2007. View at Publisher · View at Google Scholar
  3. Z. J. Lu, S. J. Deng, D. G. Huang et al., “Frontier of therapeutic antibody discovery: the challenges and how to face them,” World Journal of Biological Chemistry, vol. 3, no. 12, pp. 187–196, 2012. View at Publisher · View at Google Scholar
  4. A. A. Amara, “Pharmaceutical and industrial protein engineering: where we are?” Pakistan Journal of Pharmaceutical Sciences, vol. 26, no. 1, pp. 217–32, 2013. View at Google Scholar
  5. G. A. Sautto, R. A. Diotti, and M. Clementi, “New therapeutic options for HCV infection in the monoclonal antibody era,” New Microbiologica, vol. 35, no. 4, pp. 387–397, 2012. View at Google Scholar
  6. T. Liu, G. W. Tang, and E. Capriotti, “Comparative modeling: the state of the art and protein drug target structure prediction,” Combinatorial Chemistry and High Throughput Screening, vol. 14, no. 6, pp. 532–547, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Morea, A. M. Lesk, and A. Tramontano, “Antibody modeling: implications for engineering and design,” Methods, vol. 20, no. 3, pp. 267–279, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. G. D'Arena, G. Rossi, B. Vannata et al., “Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 4, no. 1, article e2012053, 2012. View at Publisher · View at Google Scholar
  9. S. M. Ramadan, T. M. Fouad, V. Summa, S. Kh. Hasan, and F. Lo-Coco, “Acute myeloid leukemia developing in patients with autoimmune diseases,” Haematologica, vol. 97, no. 6, pp. 805–817, 2012. View at Publisher · View at Google Scholar
  10. Y. V. Kovtun, C. A. Audette, Y. Ye et al., “Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen,” Cancer Research, vol. 66, no. 6, pp. 3214–3221, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. Kirsten Achilles Poon, “Safety assessment of antibody drug conjugates,” May 2010.
  12. K. Lin and J. Tibbitts, “Pharmacokinetic considerations for antibody drug conjugates,” Pharmaceutical Research, vol. 29, no. 9, pp. 2354–2366, 2012. View at Publisher · View at Google Scholar
  13. J. R. Adair, P. W. Howard, J. A. Hartley, D. G. Williams, and K. A. Chester, “Antibody-drug conjugates—a perfect synergy,” Expert Opinion on Biological Therapy, vol. 12, no. 9, pp. 1191–1206, 2012. View at Publisher · View at Google Scholar
  14. G. Casi and D. Neri, “Antibody-drug conjugates: basic concepts, examples and future perspectives,” Journal of Controlled Release, vol. 161, no. 2, pp. 422–428, 2012. View at Publisher · View at Google Scholar
  15. U. Iyer and V. J. Kadambi, “Antibody drug conjugates—Trojan horses in the war on cancer,” Journal of Pharmacological and Toxicological Methods, vol. 64, no. 3, pp. 207–212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Morea, A. M. Lesk, and A. Tramontano, “Antibody modeling: implications for engineering and design,” Methods, vol. 20, no. 3, pp. 267–279, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Jawad, N. Yu, C. Seedhouse, K. Tandon, N. H. Russell, and M. Pallis, “Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute myeloid leukaemia,” BMC Cancer, vol. 12, no. 1, article 431, pp. 74–80, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Sinko, S. Lindert, and J. A. McCammon, “Accounting for receptor flexibility and enhanced sampling methods in computer-aided drug design,” Chemical Biology & Drug Design, vol. 81, no. 1, pp. 41–49, 2013. View at Publisher · View at Google Scholar
  19. D. Mucs and R. A. Bryce, “The application of quantum mechanics in structure-based drug design,” Expert Opinion on Drug Discovery, vol. 8, no. 3, pp. 263–276, 2013. View at Publisher · View at Google Scholar
  20. S. M. Ramadan, T. M. Fouad, V. Summa, S. K. h. Hasan, and F. Lo-Coco, “Acute myeloid leukemia developing in patients with autoimmune diseases,” Haematologica, vol. 97, no. 6, pp. 805–817, 2012. View at Publisher · View at Google Scholar
  21. D. J. O'Shannessy, M. J. Dobersen, and R. H. Quarles, “A novel procedure for labeling immunoglobulins by conjugation to oligosaccharide moieties,” Immunology Letters, vol. 8, no. 5, pp. 273–277, 1984. View at Publisher · View at Google Scholar · View at Scopus